ClinicalTrials.gg
RecruitingNCT03676504Updated Jul 29, 2024

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

A Phase 1/2 interventional study of CD19.CAR T Cells and Fludarabine in Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric and Chronic Lymphocytic Leukemia, sponsored by University Hospital Heidelberg. Recruiting at 2 sites in Germany. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2024-07-29.

Sponsored by University Hospital Heidelberg · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2018; still recruiting 8 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Germany — 20 open to participants now, 28 under way, 8 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Germany.

Planned enrollment
69th of 116
68 · median 89
Started
2018
with 6 others
Phase 1/2
24 of 129
6 open now
Primary completion
2026-12
later than 6 of 27 live
Registered
100th of 129
by date

Among the 129 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Germany, this one is the 69th largest by planned enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2018, is one of 24 in phase 1/2, reaches primary completion later than 6 of the 27 other live ones, and was the 100th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

20 of the 129 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Germany, or all of them as a file.
02

Study summary

Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) or mantle cell lymphoma (MCL) (stratum II) as well as paediatric patients with r/r ALL (stratum III) will be treated with autologous T-lymphocytes transduced by the third-generation RV-SFG.CD19.CD28.4-1BBzeta retroviral vector. The main purpose of this study is to evaluate safety and feasibility of escalating CD19.CAR T cell doses (0,1-20×20\^7 transduced cells/m\^2) after lymphodepletion with fludarabine and cyclophosphamide.

03

Conditions studied

  • Acute Lymphoblastic Leukemia, Adult
  • Acute Lymphoblastic Leukemia, Pediatric
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Stratum I/II (Adults):

  • Confirmed CD19+ ALL, CLL, DLBCL, FL or MCL in patients ≥ 18 years
  • ALL (Ph+ and Ph-): Confirmed CD19+ ALL by cytology and flow cytometry (FACS) AND
  • disease (including "molecular relapse" with minimal residual disease (MRD) levels > 10\^-3 at two occasions > 2 weeks apart) with confirmed CD19 expression on malignant cells in relapse

    • Any relapse after stem cell transplantation (alloSCT) (≥ 6 months from alloSCT at time of CAR T cell infusion) OR
    • Any relapse failing to achieve an MRD level of \< 10\^-3 after ≥ 2 OR
    • Primary refractory as defined by not achieving a complete remission (CR) after ≥ 2 lines of treatment
  • CLL/NHL: Confirmed CD19+ CLL/NHL (including CLL, DLBCL, FL or MCL) with

    • CLL in need of treatment with:

      1. Early relapse (within 2 years) after end of chemoimmunotherapy or chemoimmunotherapy refractoriness plus failure or intolerance of both Bruton's tyrosine kinase Inhibitor (BTKi) and B-cell lymphoma 2 inhibitors (BCL-2i) OR
      2. Relapse after alloSCT, ineligible for or refractory to standard interventions (donor lymphocyte infusions (DLI), CD20 antibodies, chemoimmunotherapy)
    • DLBCL with:

      1. Refractoriness to a 2nd or later line of chemoimmunotherapy OR
      2. Relapse after autologous stem cell transplantation (autoSCT) plus ineligibility for alloSCT (including refractoriness to one line of salvage chemoimmunotherapy) OR
      3. Relapse after alloSCT
    • FL in need of treatment with:

      1. Relapse \<2 years after chemoimmunotherapy AND ineligibility for or failure of autologous stem cell transplantation (autoSCT) AND ineligibility for or failure of idelalisib OR
      2. Relapse after alloSCT, ineligible for or refractory to standard interventions (DLI, CD20 antibodies, chemoimmunotherapy)
    • MCL with:

      1. Relapse after standard first-line therapy AND ineligibility for or failure to BTKi salvage therapy OR
      2. Relapse after alloSCT AND ineligibility for or failure to BTKi salvage therapy
  • /MRD at time of enrollment
  • ≥ 12 weeks
  • (ECOG) performance status ≤ 2 at the time of screening
  • Adequate organ function:

    • Renal function defined as: serum creatinine of ≤ 2 x or estimated (eGFR) ≥ 30 mL/min/1.73 m\^2
    • Liver function defined as:
    • ≤ 5 times the ULN for the respective age
    • ≤ 2.0 mg/dl with the exception of patients with hyperbilirubinemia explained by Gilbert-Meulengracht syndrome (may be included if total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN) or extrahepatic disease (e.g. chronic hemolytic anemia)
    • minimum level of pulmonary reserve defined as ≤ grade 1 dyspnea and pulse oxygenation > 90% on room air
    • Hemodynamic stability and (LVEF) ≥ 40% as confirmed by echocardiogram
    • (ANC) ≥ 500/mm3
    • Absolute lymphocyte count (ALC) ≥ 100/mm3
  • Women of (defined as all women physiologically capable of becoming pregnant) and all male participants must agree to use highly effective methods of for one year following CD19.CAR T cell therapy
  • Ability to understand the nature of the trial and the trial related procedures
  • Written must be obtained prior to any screening procedures

Stratum III (Children and Adolescents with ALL):

  • Age of > 3 years until \< 18 years at the time of screening
  • CD19+ ALL (Ph+ and Ph-) confirmed by cytology and flow cytometry (FACS) AND
  • Relapsed or refractory disease (including "molecular relapse" with polymerase chain reaction (PCR) MRD > 10\^-3 at two occasions > 2 weeks apart) with confirmed CD19 expression on malignant cells in relapse

    • Any relapse after alloSCT (≥ 6 months from alloSCT at time of CAR T cell infusion) OR
    • Any relapse failing to achieve an MRD level of \< 10\^-3 after ≥ 2 lines of treatment OR
    • Primary refractory as defined by not achieving a CR after ≥ 2 lines of treatment
  • Measurable disease/MRD at time of enrollment
  • Life expectancy ≥ 12 weeks
  • ECOG performance status ≤ 2 (age ≥ 16 years) or Lansky performance status ≥ 50 (age \< 16 years) at the time of screening
  • Adequate organ function:

    • Renal function defined as serum creatinine-clearance ≥ 30 mL/min/1.73 m\^2
    • Liver function defined as:
    • ALT ≤ 5 times the ULN for the respective age
    • Bilirubin ≤ 2.0 mg/dl with the exception of patients with hyperbilirubinemia explained by Gilbert-Meulengracht syndrome or extrahepatic disease (e.g. chronic hemolytic anemia)
    • minimum level of pulmonary reserve defined as ≤ grade 1 dyspnea and pulse oxygenation > 90% on room air
    • Hemodynamic stability and LVEF ≥ 40% or shortening fraction > 29% as confirmed by echocardiogram
    • ANC) ≥ 500/mm3
    • ALC ≥ 100/mm3
  • Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and postpubertal male participants must agree to use highly effective methods of contraception for one year following CD19.CAR T cell therapy
  • Written informed consent of the study patient and/or the legal representative must be obtained prior to any screening procedures

Exclusion criteria

Exclusion Criteria:

Stratum I/II (Adults):

  • The following medications are excluded:

    • medication with the exception of ≤ 30 mg prednisolone/d or equivalent at the time of CAR T cell transfusion
    • Bridging/maintenance therapy including chemo- and immunotherapy must be stopped ≥ 2 weeks prior to leukapheresis, but can be continued between leukapheresis and lymphodepletion
  • Intrathecal chemotherapy is possible at any time, but not during lymphodepletion until 14 days after CD19.CAR T cell transfusion
  • Any DLI must be completed > 6 weeks prior to CD19.CAR T cell infusion
  • Florid/acute or chronic (GvHD)
  • Uncontrolled active or C
  • -positivity
  • Uncontrolled acute life-threatening bacterial, viral or fungal infection
  • Severe concomitant disease (e.g. uncontrolled arterial hypertension, heart failure (NYHA) III-IV, uncontrolled diabetes mellitus, uncontrolled hyperlipidemia)
  • Unstable angina and/or myocardial infarction within 3 months prior to screening
  • Any previous or concurrent .

The following exceptions do NOT constitute exclusion criteria:

  • Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
  • In situ carcinoma of the cervix or breast, treated curatively without evidence of recurrence ≥ 3 years prior to the study
  • CLL or FL transformed into an aggressive B cell lymphoma
  • A primary malignancy which is in complete remission for ≥ 5 years

    • Pregnant or nursing (lactating) women
    • Intolerance to the of the cell product
    • Active central nervous System (CNS) involvement in ALL patient at the time of screening is not an exclusion criterion, but patients with CNS 3 status at clinical screening (d-14) are not eligible for CD19.CAR T cell transfusion
    • Participation in another clinical trial at the time of screening

Stratum III (Children and Adolescents with ALL):

  • The following medications are excluded:

    • immunosuppressive medication with the exception of \< 0.5 mg/d*kg body weight (BW) prednisolone-equivalent at the time of CD19.CAR T cell transfusion
    • Bridging/Maintenance therapy including chemo- and immunotherapy must be stopped ≥ 2 weeks prior to leukapheresis, but can be continued between leukapheresis and lymphodepletion
  • Intrathecal chemotherapy is possible at any time, but not during lymphodepletion until 14 days after CD19.CAR T cell transfusion
  • Any DLI must be completed > 6 weeks prior to CD19.CAR T cell infusion
  • Florid/acute or chronic GvHD
  • Uncontrolled active hepatitis B or C
  • HIV-positivity
  • Uncontrolled acute life-threatening bacterial, viral or fungal infection
  • Severe concomitant disease (e.g. any life-limiting genetic disorder). Patients with Down Syndrome will not be excluded.
  • Any previous or concurrent malignancy.

The following exceptions do not constitute exclusion criteria:

  • Lymphoblastic lymphoma transformed into a CD19+ acute lymphoblastic leukemia
  • A primary malignancy which is in complete remission for ≥ 5 years

    • Pregnant or nursing (lactating) women
    • Intolerance to the excipients of the cell product
    • Active CNS involvement at the time of screening is not an exclusion criterion, but patients with CNS 3 status at clinical screening (d-14) are not eligible for CD19.CAR T cell transfusion
    • Participation in another clinical trial at the time of screening
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Stratum I

    Adult patients with relapsed or refractory ALL

    Biological: CD19.CAR T Cells · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Stratum II

    Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL

    Biological: CD19.CAR T Cells · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Stratum III

    Pediatric patients with relapsed or refractory ALL

    Biological: CD19.CAR T Cells · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalCD19.CAR T Cells

    Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2

  • 3 days of fludarabine 30 mg/m\^2/day

  • 3 days of cyclophosphamide 500 mg/m\^2/day

06

What researchers measure

Primary outcomes

  1. Safety of CD19.CAR T cell administration assessing grade and frequency of toxicities including cytokine release syndrome (CRS) and neurotoxicity according to Common Toxicity Criteria for Adverse Events (CTCAE)

    Time frame: Up to 90 days after CD19.CAR T cell administration

  2. Feasibility of CD19.CAR T cell manufacturing assessing the number of transduced T cells

    Time frame: Within 45 days prior to CD19.CAR T cell administration

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Schubert ML, Schmitt A, Sellner L, Neuber B, Kunz J, Wuchter P, Kunz A, Gern U, Michels B, Hofmann S, Huckelhoven-Krauss A, Kulozik A, Ho AD, Muller-Tidow C, Dreger P, Schmitt M. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644. PubMed 31110096 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Dec 2026, 99 months after the start.

Of 81 non-industry phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 119. This study's planned 99 months is above that.

Counting every sponsor, half of 114 studies reached it within 79 months; a quarter within 56 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2018
First posted
Sep 18, 2018
StartActual
Sep 7, 2018
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jul 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03676504
Responsible party
Prof. Dr. Michael Schmitt (Head of the GMP Core Facility University Hospital Heidelberg, Principal Investigator, Clinical Professor for Cellular Immunotherapy, University Hospital Heidelberg) — Principal investigator
First posted
Sep 18, 2018
Start date
Sep 7, 2018
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 29, 2024

Study contacts

Prof. Dr. Michael Schmitt
Contact
michael.schmitt@med.uni-heidelberg.de
+49-6221-566614
Prof. Dr. Michael Schmitt
principal investigator · University Hospital Heidelberg, Department V
Prof. Dr. Andreas Kulozik
principal investigator · University Hospital Heidelberg, University Medical Center for Children and Adolescents

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion